Navigation Links
Drug-Device Combination Market Worth US$18.54 Billion by 2014

WILMINGTON, Delaware, July 28 /PRNewswire/ -- According to a new market research report, 'Drug-Device Combination Market (2009 - 2014)', published by MarketsandMarkets (, the total drug-device combination market is expected to be worth US$18.54 billion by 2014, out of which the U.S. market will account for nearly 30.9% of the total revenues. The global market is expected to record a CAGR of 11.8% from 2009 to 2014.

Browse 144 market data tables and in-depth TOC on drug-device market. Early buyers will receive 10% customization of reports


(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

The drug-device combination market ( Market-Reports/drug-and-device-combination-101.html ) includes all the products that are a combination of drugs and devices and can be chemically or physically united or co-packaged as separate, cross labeled products. The market is driven by the growing demand for treating only the ; targeted area, increasing incidences of infections associated with regular medical devices, need for faster healing, and overall reduced cost of treatment and accelerated approval process of the drug-device combination products.

(Due to the length of the URL in the above paragraph, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

The drug eluting stents (DES) market is the largest segment and is expected to reach US$8.47 billion by 2014 at a CAGR of 9.3%. The antimicrobial catheter market is estimated to grow to a size of US$1.23 billion in 2014 which presents the highest growth potential with an expected growth rate of 23.4% in 2014. The cardiovascular treatment market is estimated to record revenues of US$9.59 billion in 2014 on account of the fact that cardiovascular diseases are one of the primary causes of death globally.

The European market is the largest geographical segment; and is expected to be worth US$7.25 billion by 2014. Its 11.2% CAGR for 2009 to 2014 is driven by the growing ageing population and the improvements in medical science and biotechnology that enables new product development. The second largest segment is the U.S. with a CAGR of 8.7% for 2009 to 2014. It is expected to reach US$5.73 billion by 2014.

The report is titled 'Drug-Device Combination Market (2009-2014) and was published in July 2009.

Scope of the Report

This report aims to identify the specific segments that offer the highest growth potential in the near future; compares the products in respect to the relative entry barriers and expected new product developments in those segments. The report discusses the segmentation of the global drug-device combination as follows:

1. Drug device combination - products

Antimicrobial catheter, advanced wound care products, bone graft substitutes, antibiotic bone cements, drug eluting stents, photodynamic therapy, closed loop glucose monitor and insulin pump, steroid eluting electrodes and others.

2. Drug device combination - application

Bone treatment, cancer treatment, diabetes treatment, skin care treatment, antimicrobial applications, urological treatment, non cardiovascular treatment, cardiovascular treatment, ophthalmic treatment, others.

3. Drug device combination - technology

Bone graft substitutes- synthetic bone graft substitutes, demineralised bone matrix and bone morphogenic proteins.

Contact our representative to sponsor this report

About MarketsandMarkets

MarketsandMarkets is a research and consulting firm that publishes 120 market research ( reports per year. Each strategically analyzed report contains 250 pages of valuable market data, including more than 100 market data Summary tables and in-depth, five-level segmentation for each of the products, services, applications, technologies, ingredients and stakeholders categories. Our reports also analyze about 200 patents, over 50 companies and micro markets that are mutually exclusive and collectively exhaustive. Browse all our 120 titles at

    Ms. Sunita
    108, West 13th Street,
    DE, 19801
    County of New Castle
    Tel: +1-888-989-8004

SOURCE MarketsandMarkets
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
2. 96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy
3. Combination Therapy Best for Aggressive Prostate Cancer
4. Particle Sciences Further Expands Combination Product Development Capabilities
5. QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
6. Abbotts TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
7. QLT announces positive results from the evaluation of Visudyne(R) combination therapy
8. 2-drug combination appears safe and active in metastatic kidney cancer
9. New treatment combination proves safe for head and neck cancer patients
10. Study shows drug combination improves outcome for advanced non-small cell lung cancer
11. Chemotherapy combination outcomes differ for aged, younger colon cancer patients
Post Your Comments:
(Date:11/30/2015)... ... 30, 2015 , ... Holcomb – Kreithen Plastic Surgery ... practices in Florida, is proud to announce that Dr. Joshua Kreithen, one of ... Inc., a Johnson & Johnson Company. , Ethicon is a global medical device ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” ... three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, ...
(Date:11/30/2015)... New York, New York (PRWEB) , ... November 30, 2015 , ... ... at the Greater New York Dental Meeting. Their Ecosystem empowers dentists to make complex ... Dentists who visit the booth will receive a free fee survey with 10 procedures ...
(Date:11/30/2015)... ... , ... The successful filing of an Investigational New Drug application (IND) is ... this key industry segment, Regis Technologies has decided to sponsor and participate in an ... EST. , Federal law does not allow new drugs to cross state lines until ...
(Date:11/30/2015)... ... 2015 , ... Vasont Systems, a top component content management ... unites with Syncro Soft’s latest software update, oXygen XML editor Version 17.1. Users ... latest release of oXygen® XML editor and the Vasont® CCMS. , The ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015   VolitionRx Limited (NYSE MKT: ... tests for a broad range of cancer types and other ... Micro Conference, which will be held December 1 - 3 in ... VolitionRx will be David Kratochvil , Chief Financial Officer ... Investor Relations. ® blood-based tests for colorectal ...
(Date:11/30/2015)... Nov. 30, 2015  Precision Image Analysis Inc. ... pleased to announce a dramatic expansion of its ... Building on its ISO-9001:2008 certification for its Quality ... Core Lab protocols and procedures. This expansion enables ... activities.  Their Core Lab services include design and ...
(Date:11/30/2015)... BOSTON , November 30, 2015 ... medicines directed at up to 10 G protein-coupled receptor ... PFE ) to research and develop potential new medicines ... targets across multiple therapeutic areas. --> Heptares ... development company and wholly-owned subsidiary of Sosei Group Corporation ...
Breaking Medicine Technology: